246 related articles for article (PubMed ID: 18827360)
1. Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation.
Ghosh A; Bhaumik UK; Bose A; Mandal U; Gowda V; Chatterjee B; Chakrabarty US; Pal TK
Biol Pharm Bull; 2008 Oct; 31(10):1946-51. PubMed ID: 18827360
[TBL] [Abstract][Full Text] [Related]
2. In-vitro and in-vivo correlation for two gliclazide extended-release tablets.
Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK
J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192
[TBL] [Abstract][Full Text] [Related]
3. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets.
Takka S; Sakr A; Goldberg A
J Control Release; 2003 Feb; 88(1):147-57. PubMed ID: 12586512
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers.
Dhawan S; Singh B; Garg SK; Hota D; Dash RJ; Singla AK; Sinha VR
Clin Pharmacokinet; 2006; 45(3):317-24. PubMed ID: 16509763
[TBL] [Abstract][Full Text] [Related]
6. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation.
Eddington ND; Marroum P; Uppoor R; Hussain A; Augsburger L
Pharm Res; 1998 Mar; 15(3):466-73. PubMed ID: 9563079
[TBL] [Abstract][Full Text] [Related]
7. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
8. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.
Mittapalli RK; Nuthalapati S; Delke DeBord AE; Xiong H
Pharm Res; 2017 Jun; 34(6):1187-1192. PubMed ID: 28243955
[TBL] [Abstract][Full Text] [Related]
9. Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: establishment of level A IVIVC.
Sankalia JM; Sankalia MG; Mashru RC
J Control Release; 2008 Jul; 129(1):49-58. PubMed ID: 18456362
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation.
Sirisuth N; Augsburger LL; Eddington ND
Biopharm Drug Dispos; 2002 Jan; 23(1):1-8. PubMed ID: 11891668
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
12. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers.
Balan G; Timmins P; Greene DS; Marathe PH
J Pharm Sci; 2001 Aug; 90(8):1176-85. PubMed ID: 11536222
[TBL] [Abstract][Full Text] [Related]
13. Once-a-day controlled-release dosage form of divalproex sodium II: development of a predictive in vitro drug release method.
Qiu Y; Garren J; Samara E; Cao G; Abraham C; Cheskin HS; Engh KR
J Pharm Sci; 2003 Nov; 92(11):2317-25. PubMed ID: 14603516
[TBL] [Abstract][Full Text] [Related]
14. Convolution and validation of in vitro-in vivo correlation of water-insoluble sustained-release drug (domperidone) by first-order pharmacokinetic one-compartmental model fitting equation.
Bose A; Wui WT
Eur J Drug Metab Pharmacokinet; 2013 Sep; 38(3):191-200. PubMed ID: 23264125
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide.
Defang O; Shufang N; Wei L; Hong G; Hui L; Weisan P
Drug Dev Ind Pharm; 2005 Aug; 31(7):677-85. PubMed ID: 16207615
[TBL] [Abstract][Full Text] [Related]
16. Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate.
Gonçalves de Lima L; Rossi de Campos D
Drug Res (Stuttg); 2016 May; 66(5):225-9. PubMed ID: 26697891
[TBL] [Abstract][Full Text] [Related]
17. Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications.
Modi NB; Lam A; Lindemulder E; Wang B; Gupta SK
Biopharm Drug Dispos; 2000 Nov; 21(8):321-6. PubMed ID: 11514951
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs.
Kulkarni R; Yumibe N; Wang Z; Zhang X; Tang CC; Ruterbories K; Cox A; McCain R; Knipp GT
J Pharm Sci; 2012 Nov; 101(11):4327-36. PubMed ID: 22899546
[TBL] [Abstract][Full Text] [Related]
19. In-vivo/in-vitro correlation of four extended release formulations of pseudoephedrine sulfate.
Mojaverian P; Rosen J; Vadino WA; Liebowitz S; Radwanski E
J Pharm Biomed Anal; 1997 Jan; 15(4):439-45. PubMed ID: 8953486
[TBL] [Abstract][Full Text] [Related]
20. In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets.
Yaro P; He X; Liu W; Xun M; Ma Y; Li Z; Shi X
Drug Dev Ind Pharm; 2014 Dec; 40(12):1670-6. PubMed ID: 24102615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
